共 6 条
[1]
Genomic profile; smoking; and response to anti-PD-1 therapy in non-small cell lung carcinoma[J] Matthew Hellmann;Naiyer Rizvi;Jedd D. Wolchok;Timothy A. Chan Molecular & Cellular Oncology 2016,
[2]
Anti-PD-1/PD-L1 therapy of human cancer: past; present; and future[J] Chen; Lieping;Han; Xue Journal of Clinical Investigation 2015,
[3]
Programmed cell death-1 inhibition in lymphoma[J] Eliza A Hawkes;Andrew Grigg;Geoff Chong The Lancet Oncology 2015,
[4]
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised; controlled; open-label; phase 3 trial[J] Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi;Ralf Gutzmer;Bart Neyns;Christoph Hoeller;Nikhil I Khushalani;Wilson H Miller;Christopher D Lao;Gerald P Linette;Luc Thomas;Paul Lorigan;Kenneth F Grossmann;Jessica C Hassel;Michele Maio;Mario Sznol;Paolo A Ascierto;Peter Mohr;Bartosz Chmielowski;Alan Bryce;I
[5]
Activity and safety of nivolumab; an anti-PD-1 immune checkpoint inhibitor; for patients with advanced; refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2; single-arm trial[J] Naiyer A Rizvi;Julien Mazières;David Planchard;Thomas E Stinchcombe;Grace K Dy;Scott J Antonia;Leora Horn;Hervé Lena;Elisa Minenza;Bertrand Mennecier;Gregory A Otterson;Luis T Campos;David R Gandara;Benjamin P Levy;Suresh G Nair;Gérard Zalcman;Jürgen Wolf;Pierre-Jean Souquet;Editta Baldini;Federico C
[6]
The PD-1/PD-Ls pathway and autoimmune diseases[J] Suya Dai;Ru Jia;Xiao Zhang;Qiwen Fang;Lijuan Huang Cellular Immunology 2014,